Research Progress of PARP Inhibitor Monotherapy and CombinationTherapy for Endometrial Cancer / Ke Shen, Li Yang, Fei-Yan Li, Feng Zhang, Lei-Lei Ding, Jing Yang, Jie Lu, Nan-Nan Wang, Yan Wang
Endometrial cancer is one of the three most common malignant tumors in the female reproductivesystem. Advanced and recurrent endometrial cancers have poor prognoses and lack effectivetreatments. Poly (ADP-ribose) polymerase (PARP) inhibitors have been applied to manydifferent types of tumors, and they can selectively kill tumor cells that are defective in homologousrecombination repair. Endometrial cancer is characterized by mutations in homologous recombinationrepair genes; accordingly, PARP inhibitors have achieved positive results in off-label treatmentsof endometrial cancer cases. Clinical trials of PARP inhibitors as monotherapies and withincombination therapies for endometrial cancer are ongoing. For this review, we searched PubMedwith “endometrial cancer” and “PARP inhibitor” as keywords, and we used “olaparib”, “rucaparib”,“niraparib” and “talazoparib” as search terms in clinicaltrials.gov for ongoing trials. The literaturesearch ended in October 2020, and only English-language publications were selected. Multiplestudies confirm that PARP inhibitors play an important role in killing tumor cells with defectsin homologous recombination repair. Its combination with immune checkpoint inhibitors,PI3K/AKT/mTOR pathway inhibitors, cell cycle checkpoint inhibitors, and other drugs can improvethe treatment of endometrial cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Current drug targets - 23(2022), 2, Seite 11 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shen, Ke [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (11 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL011162694 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011162694 | ||
| 003 | DE-627 | ||
| 005 | 20231128080534.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230613s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL011162694 | ||
| 035 | |a (KFL)prod_DARH_.F9A429F009C33A7F3931C98E83DDD71E7D82DBF0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Shen, Ke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Research Progress of PARP Inhibitor Monotherapy and CombinationTherapy for Endometrial Cancer |c Ke Shen, Li Yang, Fei-Yan Li, Feng Zhang, Lei-Lei Ding, Jing Yang, Jie Lu, Nan-Nan Wang, Yan Wang |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 Online-Ressource (11 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Endometrial cancer is one of the three most common malignant tumors in the female reproductivesystem. Advanced and recurrent endometrial cancers have poor prognoses and lack effectivetreatments. Poly (ADP-ribose) polymerase (PARP) inhibitors have been applied to manydifferent types of tumors, and they can selectively kill tumor cells that are defective in homologousrecombination repair. Endometrial cancer is characterized by mutations in homologous recombinationrepair genes; accordingly, PARP inhibitors have achieved positive results in off-label treatmentsof endometrial cancer cases. Clinical trials of PARP inhibitors as monotherapies and withincombination therapies for endometrial cancer are ongoing. For this review, we searched PubMedwith “endometrial cancer” and “PARP inhibitor” as keywords, and we used “olaparib”, “rucaparib”,“niraparib” and “talazoparib” as search terms in clinicaltrials.gov for ongoing trials. The literaturesearch ended in October 2020, and only English-language publications were selected. Multiplestudies confirm that PARP inhibitors play an important role in killing tumor cells with defectsin homologous recombination repair. Its combination with immune checkpoint inhibitors,PI3K/AKT/mTOR pathway inhibitors, cell cycle checkpoint inhibitors, and other drugs can improvethe treatment of endometrial cancer | ||
| 700 | 1 | |a Yang, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Fei-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Lei-Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Nan-Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug targets |d Hilversum : Bentham Science Publ., 2000 |g 23(2022), 2, Seite 11 |h Online-Ressource |w (DE-627)KFL000006351 |w (DE-600)2044606-8 |w (DE-576)273880896 |x 1873-5592 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:2 |g pages:11 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1389-4501&volume=23&issue=2&spage=145 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_DARH_03 | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 2 |h 11 | ||